Innovative Approach to Chronic Urticaria: Targeting MRGPRX2 Explained
Chronic Spontaneous Urticaria: A Persistent Challenge
Chronic spontaneous urticaria (CSU) continues to pose significant challenges for both patients and healthcare providers. Despite the availability of treatments such as antihistamines, omalizumab, and various immunosuppressive therapies, a notable proportion of patients still suffer from enduring symptoms including persistent wheals, angioedema, and a diminished quality of life. This ongoing issue has sparked renewed interest in exploring mast cell pathways that extend beyond the traditional IgE–FcεRI pathway.
Research Presentation at AAAAI 2026
At the forthcoming 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, Septerna is set to unveil phase 1 data regarding SEP-631, an innovative oral small molecule that targets the Mas-related G protein-coupled receptor X2 (MRGPRX2).
Study Overview
The presentation will focus on a first-in-human, proof-of-mechanism study aimed at assessing whether the selective inhibition of MRGPRX2 can mitigate mast cell–mediated skin reactions in human subjects. The rationale for focusing on MRGPRX2 lies in its emerging relevance within the context of mast cell activation.
Why Target MRGPRX2?
Over the past decade, MRGPRX2 has gained recognition as a clinically significant mast cell receptor that operates independently of IgE-mediated activation. It is predominantly expressed in connective tissue mast cells, particularly within the skin, and is responsive to a diverse array of cationic ligands, including neuropeptides, antimicrobial peptides, and various medications known to trigger pseudoallergic reactions.
When activated, MRGPRX2 prompts swift mast cell degranulation, leading to the release of histamine and other inflammatory mediators. In the context of CSU, where mast cell activation plays a crucial role but is frequently insufficiently explained by IgE-related mechanisms, MRGPRX2 has been identified as a potential contributor to disease exacerbation, particularly among patients who do not fully respond to anti-IgE treatments.
Mechanism and Development of SEP-631
SEP-631 is characterized as a selective, orally administered small molecule that functions as a negative allosteric modulator of MRGPRX2.
Rather than competing directly with natural ligands at the primary binding site, this form of negative allosteric modulation aims to reduce receptor signaling by modifying the receptor’s conformation. This approach has the potential to enhance selectivity and minimize off-target effects, which are common concerns associated with therapies targeting G protein-coupled receptors (GPCRs).
Preclinical research referenced by Septerna has demonstrated that SEP-631 effectively produces robust and sustained inhibition of human MRGPRX2 signaling. In mouse models genetically engineered to express the human receptor, the compound successfully blocked mediator-induced vascular leakage in the skin, serving as a surrogate marker for mast cell-driven inflammation.
Phase 1 Study Design and Methodology
The phase 1 trial to be presented at AAAAI is designed as a proof-of-mechanism study, not primarily focused on efficacy in CSU patients.
According to the poster title, researchers utilized an icatibant skin challenge to elicit a localized mast cell–mediated response. Icatibant, known for its role as a bradykinin B2 receptor antagonist, is recognized for inducing wheal-and-flare reactions when injected intradermally, thus serving as a controlled inflammatory stimulus.
Innovative Imaging Techniques
A noteworthy aspect of the study is the implementation of **short-wave infrared (SWIR)** imaging to evaluate treatment responses. This advanced imaging technique allows for noninvasive visualization of changes in tissue perfusion and fluid extravasation beneath the skin’s surface, offering a potentially more quantitative and objective assessment compared to conventional visual scoring methods.
The poster, titled “First-In-Human, Proof-of-Mechanism Phase 1 Study of the Oral MRGPRX2 Antagonist SEP-631 Utilizing Short Wave Infrared Imaging to Assess Response to an Icatibant Skin Challenge,” will be showcased during the Late Breaking Poster Session at the event.
Understanding Early-Phase Data
The primary objectives of any phase 1 study are to evaluate safety, tolerability, and evidence of biological activity, rather than to assess clinical efficacy. While demonstrating inhibition of a provoked skin response would support the engagement of the target, it does not necessarily predict a therapeutic benefit in the complex, multifactorial context of CSU.
Nonetheless, showing measurable modulation of mast cell–driven responses in humans would mark a significant advancement for the field. It would also help substantiate MRGPRX2 as a viable drug target and guide the design of future trials targeting patients with CSU or other conditions involving mast cell activation.
Broader Implications Beyond CSU
Beyond CSU, MRGPRX2 has been linked to various conditions where mast cells play a pivotal role, including asthma, atopic dermatitis, interstitial cystitis, and migraine. The extent to which inhibiting this receptor may translate into meaningful clinical benefits across these indications remains an open question.
For healthcare professionals, SEP-631 and similar agents present the prospect of more targeted oral therapies that address non-IgE mediated mast cell activation pathways. However, considerations regarding patient selection, long-term safety, and the potential for combination with existing treatments will need thorough evaluation in subsequent clinical phases.
Future Prospects
The findings presented at AAAAI 2026 will provide an early insight into the clinical viability of MRGPRX2 inhibition. While it is premature to draw definitive conclusions about its therapeutic impact, the study highlights an increasing initiative to transition from mere symptom management toward mechanism-based treatment strategies in CSU.
As additional information becomes available, clinicians will be keenly observing whether this novel approach can significantly broaden the treatment landscape for patients grappling with refractory conditions.
Sources
- Greenberger PA. Chronic urticaria: new management options. World Allergy Organ J. Published 2014 Nov 5. doi:10.1186/1939-4551-7-31
- Septerna to present data from phase 1 clinical trial of SEP-631 for the treatment of mast cell-driven diseases at 2026 AAAAI annual meeting. Published February 10, 2026. Accessed February 10, 2026. https://ir.septerna.com/news-releases/news-release-details/septerna-present-data-phase-1-clinical-trial-sep-631-treatment